Not finding it? Sign in to also search OpenAlex live.
-
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Judith S. E. Quik, Marieke A. Vollebergh, Valesca P. Retèl, Karen van der Sluis, Willem J. Koemans, Rosa T. van der Kaaij, +18 more
8citations -
PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC2024 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations Open access
Gerrina Ruiter, M-J. Ahn, Kiyotaka Yoh, Jon Zugazagoitia, Yi-Long Lung Cancer Wu, D. Planchard, +8 more
8citations -
Safety and functional outcome analysis of ventriculoperitoneal shunt placement for hydrocephalus within the critical phase of possible delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage
Julien Jost, Yasin Irmak, Basil Erwin Grüter, Angelo Tortora, Serge Marbacher, Christian Musahl, +3 more
4citations -
MPN-274 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up2024 Clinical Lymphoma Myeloma & Leukemia conference-abstract Immunology and Microbiology Mast cells and histamine
Andreas Reiter, Jason R. Gotlib, Deepti H. Radia, Iván Álvarez‐Twöse, Michael W. Deininger, Tracy I. George, +27 more
4citations -
738 Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer – analysis of the international CCTG CX.5/SHAPE phase III trial2024 International Journal of Gynecological Cancer article Medicine Endometrial and Cervical Cancer Treatments Open access
Sven� Mahner, Fabian Trillsch, Janice S. Kwon, Sarah Elizabeth Ferguson, Paul Bessette, Gwénaël Ferron, +14 more
3citations -
Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
Paolo Giovanni Nuciforo, John Townend, Cristina Saura, E. de Azumbaja, Florentine Hilbers, Anna Manukyants, +13 more
3citations -
OP0147 THE SLE-DAS REMISSION AND LOW DISEASE ACTIVITY STATES DISCRIMINATE DRUG FROM PLACEBO AND BETTER HEALTH-RELATED QUALITY OF LIFE: POST-HOC ANALYSIS OF THE BLISS-52 AND BLISS-76 PHASE III TRIALS.2citations
-
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial2025 Obstetrical & Gynecological Survey article Medicine Endometrial and Cervical Cancer Treatments Open access
Cathalijne Post, Stephanie M. de Boer, Melanie E. B. Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, +23 more
1citations -
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
Reproducibility of statistically significant phase III oncology trials: An In Silico meta-epidemiological analysis2025 European Journal of Cancer article Mathematics Statistical Methods in Clinical Trials Open access
Alexander Dean Sherry, Pavlos Msaouel, Avital M. Miller, Timothy A. Lin, Joseph Abi Jaoude, Ramez Kouzy, +6 more
1citations -
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Pieter Sonneveld, Philippe Moreau, Meletios Athanasios Dimopoulos, Hang Quach, P. Joy Ho, Meral Beksaç, +35 more
0citations -
WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
Jonathan Barratt, Jens Halkjaer Kristensen, Andrew M. Stone, Jürgen Floege, Vladimı́r Tesař, Hernán Trimarchi, +6 more
0citations -
#1706771 Oral octreotide capsules for treatment of acromegaly: a post hoc analysis of biochemical efficacy and safety using a pooled phase 3 clinical trial dataset
Susan Leanne Samson, Maria Fleseriu, Nienke Ruurdje Biermasz, Christian Joseph Strasburger, Shir Fuchs Orenbach, Jason A. Crompton, +1 more
0citations -
Nefecon treatment provides kidney benefits for patients with igan that extend to those with low levels of UPCR: a sub-analysis of the phase III nefigard trial2024 RWTH Publications (RWTH Aachen) article Medicine Chronic Kidney Disease and Diabetes Open access
Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Flöge, Vladimír Tesař, Hernán Trimarchi, +6 more
0citations -
Further analysis of phase III, single-dose, open-label study to investigate the efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging during cytoreductive surgery of folate receptor-positive ovarian cancer (NCT03180307)
Janos Laszlo Tanyi, Leslie M. Randall, Setsuko K. Chambers, Kristina A. Butler, Ira Seth Winer, Carrie L. Langstraat, +8 more
0citations -
Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]
Pasi Antero Janne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, +15 more
0citations -
21P: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDC*lung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study2025 Journal of Thoracic Oncology article Immunology and Microbiology Immunotherapy and Immune Responses Open access
J.F. Vansteenkiste, I. Demedts, K. Cuppens, Elvire Pons Tostivint, E. Wauters, Frank Johannes Borm, +13 more
0citations -
Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320
Avi Kenny, Janine van Duijn, One Dintwe, Jack Heptinstall, Sheetal S. Sawant, Dieter Mielke, +83 more
0citations -
MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment
Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar, Naveen Pemmaraju, Kristen Marie Pettit, +18 more
0citations -
1485P Atezolizumab plus bevacizumab before or after transarterial chemoembolization in hepatocellular carcinoma: Interim analysis of the DEMAND (AIO-HEP-0418) randomized phase II clinical trial2025 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Alexander B. Philipp, Najib Ben Khaled, Jens Ricke, Julia V. Mayerle, Dirk Waldschmidt, Ilja Kubisch, +12 more
0citations -
Nefecon treatment response in asian and white patient populations with immunoglobulin a nephropathy: a 2year analysis of the phase iii nefigard trial2024 RWTH Publications (RWTH Aachen) article Medicine Renal Diseases and Glomerulopathies Open access
Jonathan Barratt, Jens Kristensen, Andrew Stone, Jürgen Flöge, Vladimír Tesař, Hernán Trimarchi, +6 more
0citations